Aria Pharmaceuticals Files Applications for Six Provisional Patents

Published on: 

The patent applications are for programs concerning lupus, idiopathic pulmonary fibrosis, and chronic kidney disease.

Aria Pharmaceuticals, a pharmaceutical company specializing in small-molecule drugs, announced that it has filed for six provisional patents with the United States Patent and Trademark Office (USPTO) on Aug. 30, 2022. The patents concern the company’s lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.

According to a company press release, Aria developed two new chemical entities (NCEs) in each disease category, which account for the six new patent applications. The company has narrowed down the six NCEs to three lead candidates in each disease category using its Symphony drug discovery platform. The three lead candidates consist of:

  • TXR-711, an investigational treatment for lupus. This treatment inhibits targeted key signaling pathways with the goal of decreasing antibody production and cytokine expression; it is also designed to reduce inflammation through multiple pathways and processes.
  • TXR-1002, an investigational treatment for IPF. This treatment is designed to inhibit myofibroblast proliferation, collagen, transforming growth factor beta (TGF-β), fibrosis, and inflammation.
  • TXR-1210, an investigational treatment for CKD. By inhibitng pyroptosis and regulating interleukin-1 activity, TXR-1210 is designed to regulate renal inflammation and fibrosis, decrease the release of proinflammatory cytokines, and inhibit TGF-β expression.

“These filings represent significant development milestones for Aria and are in line with our strategic focus on moving our proprietary pipeline forward,” said Andrew A. Radin, CEO, Aria Pharmaceuticals, in the release. “By analyzing multiple heterogeneous data types in one process, our drug discovery platform Symphony is proving capable of discovering novel therapies where we have high confidence in their viability as novel treatments.”

“We are excited and confident in the data across all of our early-stage candidates,” said Anjali Pandey, senior vice-president of Nonclinical R&D and Chemistry, Aria, in the release. “This achievement takes us closer to our goal of moving novel treatments into clinical research, and we’re ready for the next steps needed for clinical success.”

Source: Aria Pharmaceuticals